 |
|
Compound has potential for new class of AIDS drugs
May 15, 2008ANN ARBOR, Mich.-Researchers have developed what they believe is the first new mechanism in nearly 20 years for inhibiting a common target used to treat all HIV patients, which could eventually lead to a new class of AIDS drugs.
Researchers at the University of Michigan used computer models to develop the inhibiting compound, and then confirmed in the lab that the compound does indeed inhibit HIV protease, which is an established target for AIDS treatment. The protease is necessary to replicate the virus, says Heather Carlson, U-M professor of medicinal chemistry and principal investigator of the study.
Carlson stresses this is a preliminary step, but still significant.
"It's very easy to make an inhibitor, (but) it's very hard to make a drug," said Carlson, who also has an appointment in chemistry. "This compound is too weak to work in the human body. The key is to find more compounds that will work by the same mechanism."
What's so exciting is how differently that mechanism works from the current drugs used to keep the HIV from maturing and replicating, she says. Current drugs called protease inhibitors work by debilitating the HIV-1 protease. This does the same, but in a different way, Carlson says.
A protease is an enzyme that clips apart proteins, and in the case of HIV drugs, when the HIV-1 protease is inhibited it cannot process the proteins required to assemble an active virus. In existing treatments, a larger molecule binds to the center of the protease, freezing it closed.
The new mechanism targets a different area of the HIV-1 protease, called the flap recognition pocket, and actually holds the protease open. Scientists knew the flaps opened and closed, but didn't know how to target that as a mechanism, Carlson says.
Carlson's group discovered that this flap, when held open by a very small molecule-half the size of the ones used in current drug treatments-also inhibits the protease.
In addition to a new class of drugs, the compound is key because smaller molecules have better drug-like properties and are absorbed much more easily.
"This new class of smaller molecules could have better drug properties (and) could get around current side effects," Carlson said. "HIV dosing regimes are really difficult. You have to take medicine several times in the day. Maybe you wouldn't have to do that with these smaller molecules because they would be absorbed differently."
Kelly Damm, a former student and now at Johnson & Johnson, initially had the idea to target the flaps in this new way, Carlson says.
"In a way, this works like a door jam. If you looked only at the door when it's shut, you'd not know you could put a jam in it," she said. "We saw a spot where we could block the closing event, but because everyone else was working with the closed form, they couldn't see it."
University of Michigan
"It's very easy to make an inhibitor, (but) it's very hard to make a drug," said Carlson, who also has an appointment in chemistry. "This compound is too weak to work in the human body. The key is to find more compounds that will work by the same mechanism."
What's so exciting is how differently that mechanism works from the current drugs used to keep the HIV from maturing and replicating, she says. Current drugs called protease inhibitors work by debilitating the HIV-1 protease. This does the same, but in a different way, Carlson says.
A protease is an enzyme that clips apart proteins, and in the case of HIV drugs, when the HIV-1 protease is inhibited it cannot process the proteins required to assemble an active virus. In existing treatments, a larger molecule binds to the center of the protease, freezing it closed.
The new mechanism targets a different area of the HIV-1 protease, called the flap recognition pocket, and actually holds the protease open. Scientists knew the flaps opened and closed, but didn't know how to target that as a mechanism, Carlson says.
Carlson's group discovered that this flap, when held open by a very small molecule-half the size of the ones used in current drug treatments-also inhibits the protease.
In addition to a new class of drugs, the compound is key because smaller molecules have better drug-like properties and are absorbed much more easily.
"This new class of smaller molecules could have better drug properties (and) could get around current side effects," Carlson said. "HIV dosing regimes are really difficult. You have to take medicine several times in the day. Maybe you wouldn't have to do that with these smaller molecules because they would be absorbed differently."
Kelly Damm, a former student and now at Johnson & Johnson, initially had the idea to target the flaps in this new way, Carlson says.
"In a way, this works like a door jam. If you looked only at the door when it's shut, you'd not know you could put a jam in it," she said. "We saw a spot where we could block the closing event, but because everyone else was working with the closed form, they couldn't see it."
University of Michigan
Protease Current Events and Protease News RSSNew technique reduces tobacco smoke damage to lungs in mice
Researchers in Australia have demonstrated that blocking a certain protein can reduce or prevent cigarette smoke-induced lung inflammation in mice.
HIV drug resistance lasts about 1 year in women treated with nevirapine to prevent infant infection
A new international study reported in PLoS Medicine confirms that a single dose of nevirapine (sdNVP) can lead to HIV treatment failure in women who receive the drug to prevent transmission of the AIDS virus to their infants.
Malaria's key survival protein identified, offering drug hope
Walter and Eliza Hall Institute researchers have identified a key protein used by the malaria parasite to transform human red blood cells, ensuring the parasite's survival.
Scientists find ideal target for malaria therapy
Scientists at Washington University School of Medicine in St. Louis have identified a protein made by the malaria parasite that is essential to its ability to take over human red blood cells.
Scripps Research scientists find two compounds that lay the foundation for a new class of AIDS drug
A team of scientists at The Scripps Research Institute has identified two compounds that act on novel binding sites for an enzyme used by the human immunodeficiency virus (HIV), the virus that causes AIDS. The discovery lays the foundation for the development of a new class of anti-HIV drugs to enhance existing therapies, treat drug-resistant strains of the disease, and slow the evolution of drug resistance in the virus.
Scientists discover enzyme that 'cleans' cancer cells
Dr Joerg Hartkamp and Dr Stefan Roberts have found that the protease HtrA2 can "clean" cells of the oncogene WT1, which is found at high levels in many leukaemias and solid cancers such as breast and lung cancer.
Researchers trace HIV mutations that lead to drug resistance
Chemists at UC San Diego and statisticians at Harvard University have developed a novel way to trace mutations in HIV that lead to drug resistance.
Researchers create new 'smart' nanocapsule delivery system for use in protein therapy
Protein therapy - the delivery of healthy proteins directly into human cells to replace malfunctioning proteins - is considered one of the most direct and safe approaches for treating diseases.
No-entry zones for AIDS virus
The AIDS virus inserts its genetic material into the genome of the infected cell. Scientists of the German Cancer Research Center have now shown for the first time that the virus almost entirely spares particular sites in the human genetic material in this process. This finding may be useful for developing new, specific AIDS drugs.
Alternatively spliced tissue factor identified as promising new biomarker for aggressive cancers
A recently discovered form of the protein that triggers blood clotting may play a key role in the molecular mechanisms leading to the growth of certain metastatic cancers, according to new research reported by an international team of scientists.
More Protease Current Events and Protease News Articles
 |
Houston Nutraceuticals Enzymes Peptizyde Multiple Protease 90 Capsules by Houston Nutraceuticals, Houston Enzymes Peptizyde (pronounced "Pep-ta-zyde") is a combination of three different proteolytic enzymes isolated from plant sources. Each enzyme has a unique set of peptide bonds it prefers to break, so the combination of these enzymes allows much more efficient means of quickly and thoroughly breaking down (hydrolyzing) proteins to its smaller components. The enzymes in Peptizyde work only on food proteins, not carbohydrates, fats, or other compounds, and do not interfere with medications or other supplements (unless they are also proteins, which is extremely unlikely). Peptizyde may be used in combination with other enzyme products. Peptizyde supplements the "normal" hydrolysis of casein, gluten, and other food proteins such that the exorphin peptides are not produced because the specific cleavage... |
 |
Digestive Enzymes 500 mg, 240 Caps by Source Naturals Digestive Aid Enzyme Supplement Each capsule contains 500 mg of an all-vegetarian, broad spectrum blend of digestive enzymes. |
 |
Protease Plus (90) by Nature's Sunshine Products Protease Plus provides supplemental protease enzymes that break down proteins into smaller proteins and amino acids, maximizing digestion. As we grow older, our bodies produce fewer enzymes. When a suboptimal level of protease enzyme exists, undigested proteins can pass through the intestinal tract and remain undigested. These have been linked to effects on overall health and vitality. Protease Plus may support immunity by possibly activating macrophages and natural killer cells. NSP's formula provides a full spectrum of plant-derived trace minerals, which help activate enzymes. Each capsule of NSP Protease Plus contains 60,000 HUT protease in a base of beet root fiber and plant-sourced trace mineral concentrate. Take 1 capsule with a meal three times daily for protein digestion.... |
 |
Protease Formula, 180 caps. by R-Garden Inc. Protease Formula aids in the digestion of proteins and eats up toxins the body throws off. Protease is believed to be helpful for relieving fever, infection, colds, flu, sore throat, parasites, candida, acne, depression, anxiety, fatigue and insomnia. It is usually taken between meals on an empty stomach. |
 |
Protease, High Potency (60) by Nature's Sunshine Products ############################################################################################################################################################################################################################################################### |
 |
Houston Nutraceuticals, Houston Enzymes AFP-Peptizyde Multiple Protease Powder 150 Grams providing 200 Servings by Houston Nutraceuticals, Houston Enzymes Houston Enzymes AFP-Peptizyde Multiple Protease. An All-Fungal Protease Version of Peptizyde.High-potency enzyme combination for digestion of food protein. High dipeptidylPeptidase IV (DPP IV) activity without papain. Increases breakdown of casein, gluten, soy protein. Odorless and tasteless version of original Peptizyde. Safe, non-toxic alternative or companion to GFCF diet. Devin Houston, Ph,D., acknowledged inventor and founder of Houston Nutraceuticals,Inc.(HNI) has 20 years of research experience in enzymes, receptor mechanisms,and nutritional biochemistry. HNI provides effective, safe and affordabledigestive enzymes that will help your body function better...deliveringdirect from the scientist to the consumer. An odorless and tasteless enzyme formulation designed to efficiently... |
|
Proteases as Drug Targets: Serine Proteases (Methods and Principles in Medicinal Chemistry) by Joseph P. Vacca (Editor), Raimund Mannhold (Editor), Hugo Kubinyi (Editor), Gerd Folkers (Editor) Part of a suite of three similarly organized books on proteases, the family of serine proteases is described from a drug developer's perspective. This book also contains numerous case studies from recently developed protease drugs. | |
 |
Houston Enzymes, Houston Nutraceuticals Peptizyde Multiple Protease Powder 150 Grams for 200 Servings by Houston Nutraceuticals, Houston Enzymes Peptizyde is a unique blend of thress protein-degrading enzymes formulated at high activity levels to efficiently break down all food proteins; especially casein, gluten, soy, and meat proteins. Peptizyde works in the acid environment of the stomach being formed and absorbed in the small intestine. Peptizyde is high in DPP IV (dipeptidyl peptidase IV); the only enzyme known to break down casomorphin and gluteomorphin. Working only on food proteins, Peptizyde is safe with no toxidity demonstrated at any dosing level. Other enzymes, supplements and medications may be given with Peptizyde. |
 |
NESS Enzymes Protease #4 90 caps by Ness Enzymes Protease 90 #4 caps Formula 4 All NESS enzyme activity is measured in Food Chemicals Codex (FCC) units. |
 |
RevitaZyme Probiotic Digestive Systemic Enzymes - (90 Caps- Full Month Supply) - with Amylase, Protease, Lactase, Lipase, Phytase, Cellulase PLUS Acidophilus and more! by Advanced Health and Nutrition Revitazyme helps bloating, gas, heartburn, indigestion and other uncomfortable digestive symptoms. Revitazyme also provides your system with the Probiotic "friendly bacteria" you need! Go ahead! Enjoy the foods you love! RevitaZyme heads of these nasty symptoms... before they get a chance to "cramp" your style! How Does RevitaZyme Work? RevitaZyme provides you with the natural enzymes your body needs to help break down the foods you eat. So you can eat the foods you love again, without uncomfotable symptoms. Revitazyme is formulated with the highest quality plant-derived enzymes, providing you with superior digestive support for optimal overall health. RevitaZyme alleviates the following uncomfortable digestive symptoms: * Bloating * Gas ... |
| © 2010 BrightSurf.com |